PURPOSE: Evaluation of in-vivo anticancer activity of aerosolized Celecoxib encapsulated Nanolipidcarriers (Cxb-NLC) as a single therapeutic agent and combined with intravenously administered Docetaxel (Doc) against non-small cell lung cancer. METHODS: Cxb-NLC were prepared by high-pressure homogenization and were characterized for its physicochemical characteristics. Metastatic A549 tumor model in Nu/Nu mice was used to evaluate response of aerosolized Cxb-NLC & Doc. Isolated lung tumor samples were analyzed for: a) DNA fragmentation and cleaved caspase-3 by immunohistochemistry, b) apoptotic and angiogenic protein markers by western blot, c) global proteomic alterations by an isobaric labeling quantitative proteomic method and d) toxicity studies of NLC. RESULTS: The particle size of Cxb-NLC was 217 ± 20 nm, while entrapment efficiency was more than 90%. Cxb-NLC and Doc alone and in combination showed 25 ± 4%, 37 ± 5%, and 67 ± 4% reduction in tumor size respectively compared to control. Proteomic analysis with combination treatment further revealed significantly decreased expression of multiple pro-survival and pro-metastasis proteins as well as tumor invasion markers and the expression of S100 family proteins, such as S100A6 and S100P were decreased by 2.5 and 1.6 fold. CONCLUSIONS: Combination therapy with Cxb-NLC and Doc showed significant reduction in tumor growth which was further confirmed by proteomic analysis.
PURPOSE: Evaluation of in-vivo anticancer activity of aerosolized Celecoxib encapsulated Nanolipidcarriers (Cxb-NLC) as a single therapeutic agent and combined with intravenously administered Docetaxel (Doc) against non-small cell lung cancer. METHODS:Cxb-NLC were prepared by high-pressure homogenization and were characterized for its physicochemical characteristics. Metastatic A549 tumor model in Nu/Nu mice was used to evaluate response of aerosolized Cxb-NLC & Doc. Isolated lung tumor samples were analyzed for: a) DNA fragmentation and cleaved caspase-3 by immunohistochemistry, b) apoptotic and angiogenic protein markers by western blot, c) global proteomic alterations by an isobaric labeling quantitative proteomic method and d) toxicity studies of NLC. RESULTS: The particle size of Cxb-NLC was 217 ± 20 nm, while entrapment efficiency was more than 90%. Cxb-NLC and Doc alone and in combination showed 25 ± 4%, 37 ± 5%, and 67 ± 4% reduction in tumor size respectively compared to control. Proteomic analysis with combination treatment further revealed significantly decreased expression of multiple pro-survival and pro-metastasis proteins as well as tumor invasion markers and the expression of S100 family proteins, such as S100A6 and S100P were decreased by 2.5 and 1.6 fold. CONCLUSIONS: Combination therapy with Cxb-NLC and Doc showed significant reduction in tumor growth which was further confirmed by proteomic analysis.
Authors: J A Menéndez; M del Mar Barbacid; S Montero; E Sevilla; E Escrich; M Solanas; H Cortés-Funes; R Colomer Journal: Eur J Cancer Date: 2001-02 Impact factor: 9.162
Authors: T Hida; K Kozaki; H Muramatsu; A Masuda; S Shimizu; T Mitsudomi; T Sugiura; M Ogawa; T Takahashi Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: Olga B Garbuzenko; Maha Saad; Seema Betigeri; Min Zhang; Alexandre A Vetcher; Viatcheslav A Soldatenkov; David C Reimer; Vitaly P Pozharov; Tamara Minko Journal: Pharm Res Date: 2008-10-29 Impact factor: 4.200
Authors: Susanne R Youngren-Ortiz; David B Hill; Peter R Hoffmann; Kenneth R Morris; Edward G Barrett; M Gregory Forest; Mahavir B Chougule Journal: J Aerosol Med Pulm Drug Deliv Date: 2017-03-09 Impact factor: 2.849
Authors: Thomas Iosifidis; Erika N Sutanto; Alysia G Buckley; Laura Coleman; Erin E Gill; Amy H Lee; Kak-Ming Ling; Jessica Hillas; Kevin Looi; Luke W Garratt; Kelly M Martinovich; Nicole C Shaw; Samuel T Montgomery; Elizabeth Kicic-Starcevich; Yuliya V Karpievitch; Peter Le Souëf; Ingrid A Laing; Shyan Vijayasekaran; Francis J Lannigan; Paul J Rigby; Robert Ew Hancock; Darryl A Knight; Stephen M Stick; Anthony Kicic Journal: JCI Insight Date: 2020-04-09
Authors: Apurva R Patel; Mahavir B Chougule; Ed Lim; Kevin P Francis; Stephen Safe; Mandip Singh Journal: Nanomedicine Date: 2013-12-17 Impact factor: 5.307